BACE-1和ADAM-10作为阿尔茨海默病潜在的外周生物标志物
Carlo Cervellati1, Alessandro Trentini2, Marco Zuin1
1Department of Translational Medicine and for Romagna, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy.
Current pharmaceutical design
|January 9, 2025
概括
这就是阿尔茨海默病的原因.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 粉样β (Aβ) 双平衡是阿尔茨海默病 (AD) 病理学的核心.
- 酶ADAM10 (α-分泌酶) 和BACE1调节Aβ的产生和清除.
- 大脑中这些酶的失调可能反映在外周液体中.
研究的目的:
- 审查ADAM10和BACE1在阿尔茨海默病中的作用.
- 探索它们作为AD的诊断生物标志物的潜力.
主要方法:
- 在AD的ADAM10和BACE1研究的文献综述.
- 分析它们在Aβ代谢中的参与以及作为生物标记物的潜力.
主要成果:
- ADAM10和BACE1是amyloidogenic和非amyloidogenic通路的关键调节器.
- 在ADAM10和BACE1中的异常被认为是AD病理的驱动因素.
- 这些酶在外围流体中的表达和活性发生变化表明生物标记物的潜力.
结论:
- 在阿尔茨海默氏病的发病过程中,ADAM10和BACE1起着至关重要的作用.
- 它们的活性变化和在外周液体中的存在凸显了它们作为阿兹海默症诊断的基于血液的生物标志物的承诺.
关键词:
亚当10 亚当10 亚当阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.亚博体育在线娱乐 亚博体育在线娱乐在BACE1中获得了BACE1学位.生物标志物 生物标志物痴呆症. 痴呆症. 这是一种痴呆症.更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
761
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
相关概念视频
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:22Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161